Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Late-breaking news!!!
PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”
Read the full article here.
Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients
Stay updated on the latest scientific breakthroughs with Hemostasis Today.
-
Feb 19, 2026, 16:01Honoring Black Pioneers in Hematology During Black History Month – ASH
-
Feb 19, 2026, 15:16Irina Pahlevanyan: Global Leaders on Courage, Trust, and the True Purpose of Fundraising
-
Feb 19, 2026, 15:12Stéphanie Forté: Transition Readiness in Youth With Sickle Cell Disease
-
Feb 19, 2026, 15:08Tagreed Alkaltham: Strengthening Blood Inventory Governance Through RFID Technology
-
Feb 19, 2026, 14:59Başak Taburoğlu Yılmaz: Improving Diagnosis and Care for Women With Bleeding Disorders
-
Feb 19, 2026, 14:59Munira Borhany: Moving Beyond Stereotypes in the Diagnosis of Bleeding Disorders
-
Feb 19, 2026, 14:56Flora Peyvandi: Personalized VWF Dosing Revolutionizes Surgery in VWD
-
Feb 19, 2026, 14:54Michela Mazzon: The Molecular Trigger Behind the COVID19 Vaccines-Associated ITT
-
Feb 19, 2026, 14:42Luca Palombi: Real-Time Assessment of Venous Hemodynamics During Movement With DUS